1. Anlotinib plus chemotherapy for T790M‐negative EGFR‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial. Issue 24 (8th November 2022) Authors: Li, Juan; Tian, Yuke; Zheng, Min; Ge, Jun; Zhang, Jiliang; Kong, Dejun; Chen, Mei; Yu, Ping Journal: Thoracic cancer Issue: Volume 13:Issue 24(2022) Page Start: 3496 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗